APA (7th ed.) Citation

Lang, I., Inbar, M., Kahán, Z., Greil, R., Beslija, S., Stemmer, S., . . . Zielinski, C. (2012). Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer. European Journal of Cancer, 48(17), 3140. https://doi.org/10.1016/j.ejca.2012.04.022

Chicago Style (17th ed.) Citation

Lang, I., et al. "Safety Results from a Phase III Study (TURANDOT Trial by CECOG) of First-line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER-2-negative Locally Recurrent or Metastatic Breast Cancer." European Journal of Cancer 48, no. 17 (2012): 3140. https://doi.org/10.1016/j.ejca.2012.04.022.

MLA (9th ed.) Citation

Lang, I., et al. "Safety Results from a Phase III Study (TURANDOT Trial by CECOG) of First-line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER-2-negative Locally Recurrent or Metastatic Breast Cancer." European Journal of Cancer, vol. 48, no. 17, 2012, p. 3140, https://doi.org/10.1016/j.ejca.2012.04.022.